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1.67–1.80) and gabapentin (OR 1.56–1.69). Those seen
by neurology were less likely to receive phenobarbital
(OR .68–.75) and phenytoin (OR .73–.82), and more
likely to receive gabapentin (OR 1.58–1.88) and carba-
mazepine (OR 1.28–1.35).
CONCLUSIONS: The elderly and those seen only in
primary care were more likely to receive potentially prob-
lematic medications. Despite research ﬁndings, physicians
may be reluctant to change efﬁcient medications. The
elderly tend to have more adverse effects from these 
medications, and while often subtle, they may result 
in injury and debilitation. Results highlight the need
translate clinical research into best practices, and develop
research programs that relate these practices to patient
outcomes.
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OBJECTIVES: Van Biessen (2000) concluded that: (1)
intention to treat survival was not different between
patients who started on HD and patients who started on
PD; (2) the survival of patients who started on PD and
switched to HD was better than the survival of patients
who stayed on PD; (3) the survival of patients who started
on PD and switched to HD was better than the survival
of patients who started on HD and stayed on HD (J Am
Soc Nephrol 11, 116–125, 2000). This study is a repli-
cation of the Van Biessen study, which was carried out 
in a Belgium hospital, to investigate whether these three
conclusions apply to the Netherlands. Retrospective 
incidence data was used from the Dutch national ESRD
registry (Renine).
METHODS: The Cox proportional hazards regression
model was applied to analyse survival. Age, gender and
a mortality risk factor were used as covariates. The 
mortality risk factor was derived from a classiﬁcation of
EDTA primary diagnosis in three groups according to
low, medium or high mortality risk. Survival was studied
over a 10-year period from 1990 to 2000.
RESULTS: The analyses revealed that: (1) the intention
to treat survival of patients who started on HD did not
differ from the survival of patients who started on PD.
RR: 0.96 (95% CI: 0.93–1.00); (2) the survival of patients
who started on PD and switched to HD was better than
the survival of patients who stayed on PD. RR: 0.40
(95% CI: 0.37–0.43); (3) the survival of patients who
started on PD and switched to HD was better than the
survival of patients who started on HD and stayed on
HD. RR: 0.49 (95% CI: 0.46–0.52).
CONCLUSION: All conclusions from the Van Biessen
study were conﬁrmed for the Netherlands.
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OBJECTIVES: Urinary incontinence (UI) is associated
with adverse physical, psychological and economic out-
comes effecting ~13M Americans. UI is underreported
and frequently untreated. First-line therapy includes
agents decreasing incontinence frequency. This study
characterizes utilization associated with tolterodine
immediate release (TOL) versus oxybutynin (OXY).
METHODS: Drug markers associated with UI manage-
ment in the Merck-Medco pharmacy claims database 
(N >= 65M) were used to construct a continuously 
beneﬁt-eligible, new therapy cohort from September 1,
1999–August 31, 2000. Utilization metrics were evalu-
ated through August 31, 2001. All patients were followed
for 12 months post-therapy initiation. Chronic disease
scores were used to estimate patient chronic disease
burden via drug markers during the 6 months preceding
UI initiation. Propensity scoring via logistic regression
was used to control for possible selection bias, and to
create a matched cohort (N = 36,142) based on a
minimum difference in propensity scores. Persistence was
deﬁned as any patient with drug supply on hand at least
one day in the 12th month following the index prescrip-
tion. Compliance measured the percentage of time
between the ﬁrst and last ﬁlls that the patient had drug
supply “on hand”.
RESULTS: Mean age was 62 years; 65% were female.
Eight percent of the cohort had drug markers for diabetes
(OHA or insulin) during the 6 months preceding UI
therapy. Twelve-month persistence was higher for TOL
patients than OXY patients (24.2% vs. 16.8%, p <
.0001). TOL patients were more compliant than OXY
patients (mean = 71.0% VS 64.3%, p < .0001). Compli-
ance and persistence differences were slightly more pro-
nounced in diabetics; TOL compliance mean was 75.9%
vs. OXY 65.3% (p < .0001), while 30.8% of TOL 
diabetics were persistent, compared to 19.3% of OXY
diabetics (p < .0001).
CONCLUSIONS: TOL had higher persistence and com-
pliance rates than OXY. These improvements in com-
pliance and persistence differences were slightly more
pronounced in diabetics. This data suggests that dif-
ferences exist between pharmaceutical agents used to
manage UI.
